Effects of roxadustat versus recombination human erythropoietin on coronary artery calcification in maintenance hemodialysis patients

WEN Yang; XIA Yunfeng; GAN Hua; LI Zhengrong; GONG Ying

doi:10.6039/j.issn.1001-0408.2024.05.14

您当前的位置：

首页 >

文章列表页 >

Effects of roxadustat versus recombination human erythropoietin on coronary artery calcification in maintenance hemodialysis patients

更新时间：2024-03-08

- Effects of roxadustat versus recombination human erythropoietin on coronary artery calcification in maintenance hemodialysis patients
- ZHONGGUO YAOFANG Vol. 35, Issue 5, Pages: 590-594(2024)
- 作者机构：
  
  重庆医科大学附属第一医院肾脏内科，重庆　400016
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.05.14
  CLC： R969.4;R973+.3
- Published：15 March 2024，
  
  Received：07 August 2023，
  
  Revised：20 February 2024，
扫描看全文
文杨,夏运风,甘华等.对比罗沙司他与重组人促红细胞生成素对维持性血液透析患者冠状动脉钙化的影响 ^Δ[J].中国药房,2024,35(05):590-594.

WEN Yang,XIA Yunfeng,GAN Hua,et al.Effects of roxadustat versus recombination human erythropoietin on coronary artery calcification in maintenance hemodialysis patients[J].ZHONGGUO YAOFANG,2024,35(05):590-594.
文杨,夏运风,甘华等.对比罗沙司他与重组人促红细胞生成素对维持性血液透析患者冠状动脉钙化的影响 ^Δ[J].中国药房,2024,35(05):590-594. DOI： 10.6039/j.issn.1001-0408.2024.05.14.

WEN Yang,XIA Yunfeng,GAN Hua,et al.Effects of roxadustat versus recombination human erythropoietin on coronary artery calcification in maintenance hemodialysis patients[J].ZHONGGUO YAOFANG,2024,35(05):590-594. DOI： 10.6039/j.issn.1001-0408.2024.05.14.

摘要

目的

对比罗沙司他与重组人促红细胞生成素（rHuEPO）对维持性血液透析（MHD）患者冠状动脉钙化的影响。

方法

采用回顾性分析的方法，选取重庆医科大学附属第一医院血液净化中心2019年4月至2021年6月处方中含罗沙司他的56例MHD患者作为ROX组，同期处方中含rHuEPO的60例MHD患者作为EPO组，随访观察12个月，比较两组患者治疗前后实验室检查指标、冠状动脉钙化积分（CACS）、心脏超声参数的差异及随访期间心脑血管事件发生情况。

结果

治疗前及治疗后两组患者的CACS比较，差异均无统计学意义（

＞0.05）；但ROX组患者治疗前后的CACS差值明显低于EPO组患者（

＜0.05）。两组患者治疗前后心脏超声参数及实验室检查指标比较，差异均无统计学意义（

＞0.05）。随访期间，ROX组患者的脑卒中和心肌梗死发生率显著低于EPO组（

＜0.05），但两组间因心衰住院的发生率差异无统计学意义（

＞0.05）。

结论

与rHuEPO比较，罗沙司他可能对延缓MHD患者冠状动脉钙化有积极作用，且可能有利于减少MHD患者心肌梗死、脑卒中的发生。

Abstract

OBJECTIVE

To compare the effects of roxadustat and recombination human erythropoietin （rHuEPO） on coronary artery calcification in maintenance hemodialysis （MHD） patients.

METHODS

In retrospective analysis， MHD patients prescribed roxadustat in the Blood Purification Center of the First Affiliated Hospital of Chongqing Medical University from April 2019 to June 2021 were selected as the ROX group （56 patients）， and MHD patients prescribed rHuEPO during the same period were selected as the EPO group （60 patients）， and follow-up observation was conducted for 12 months. The differences in laboratory index， coronary artery calcification score （CACS）， and cardiac ultrasound parameters before and after treatment as well as the occurrence of cardiac and cerebrovascular adverse events during follow-up period were compared between the two groups.

RESULTS

There was no statistical difference in CACS between the two groups before and after treatment （

＞0.05）； but the difference of CACS in the ROX group was significantly lower than the EPO group （

＜0.05）. There was no statistically significant difference in cardiac ultrasound parameters and laboratory indexes between the two groups before and after treatment （

＜0.05）. The incidence of apoplexy and myocardial infarction in the ROX group was lower than that in the EPO group （

＜0.05）， and there was no statistically significant difference in the incidence of hospitalization due to heart failure between the two groups （

＞0.05）.

CONCLUSIONS

Compared with rHuEPO， roxadustat may have a positive effect on delaying coronary artery calcification in MHD patients and may be beneficial in reducing the incidence of myocardial infarction and apoplexy in MHD patients.

关键词

罗沙司他重组人促红细胞生成素维持性血液透析冠状动脉钙化

Keywords

recombination human erythropoietinmaintenance hemodialysiscoronary artery calcification

references

HSU B G，TSAI J P. Vascular calcification of chronic kidney disease：a brief review[J]. Tzu Chi Med J，2020，33（1）：34-41.

LI X J，JIANG X S，HE F，et al. Effect of erythropoietin on calcification of vascular smooth muscle cells and its molecular regulatory mechanism[J]. J Cardiovasc Transl Res，2021，14（3）：525-537.

中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志，2021，101（20）：1463-1502.

Working Group on Guidelines for Renal Anemia of the Nephrology Branch of the Chinese Medical Association.Clinical practice guidelines for diagnosis and treatment of renal anemia in China[J]. Natl Med J China，2021，101（20）：1463-1502.

LI G，LU W H，AI R，et al. The relationship between serum hypoxia-inducible factor 1α and coronary artery calcification in asymptomatic type 2 diabetic patients[J]. Cardiovasc Diabetol，2014，13：52.

LI X J，LIU C X，LI Y，et al. Inflammation promotes erythropoietin induced vascular calcification by activating p38 pathway[J]. Bioengineered，2022，13（3）：5277-5291.

SURESH S，RAJVANSHI P K，NOGUCHI C T. The many facets of erythropoietin physiologic and metabolic response[J]. Front Physiol，2020，10：1534.

GREENLAND P，BLAHA M J，BUDOFF M J，et al. Coronary calcium score and cardiovascular risk[J]. J Am Coll Cardiol，2018，72（4）：434-447.

ZHOU S，QIAO Y M，LIU Y G，et al. Bone marrow derived mesenchymal stem cells pretreated with erythropoie-tin accelerate the repair of acute kidney injury[J]. Cell Biosci，2020，10（1）：130.

SUZUKI Y，MATSUMOTO N，YODA S，et al. Coronary artery calcium score：current status of clinical application and how to handle the results[J]. J Cardiol，2022，79（5）：567-571.

HANDY C E，DESAI C S，DARDARI Z A，et al. The association of coronary artery calcium with noncardiovascular disease：the multi-ethnic study of atherosclerosis[J]. JACC Cardiovasc Imaging，2016，9（5）：568-576.

NASIR K，CAINZOS-ACHIRICA M. Role of coronary artery calcium score in the primary prevention of cardiovascular disease[J]. BMJ，2021，373：n776.

ZEPPENFELD K，TFELT-HANSEN J，DE RIVA M，et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. Eur Heart J，2022，43（40）：3997-4126.

CHOW A，ROGER S，POLLOCK C，et al. Fc 071 enhanced degradation of 3-hydroxy-3-methylglutaryl coenzyme a reductase （HMGCR） may contribute to the lowering of LDL cholesterol seen with roxadustat in chronic kidney disease patients with anemia[J]. Nephrol Dial Transplant，2021，36（S1）：gfab118.001.

WANG Y，WANG P，WU Q H，et al. Loading of erythropoietin on biphasic calcium phosphate bioceramics promotes osteogenesis and angiogenesis by regulating EphB4/EphrinB2 molecules[J]. J Mater Sci Mater Med，2022，33（2）：19.

BABITT J L，EISENGA M F，HAASE V H，et al. Controversies in optimal anemia management：conclusions from a Kidney Disease：Improving Global Outcomes （KDIGO） conference[J]. Kidney Int，2021，99（6）：1280-1295.

GLUBA-BRZÓZKA A，FRANCZYK B，OLSZEWSKI R，et al. The influence of inflammation on anemia in CKD patients[J]. Int J Mol Sci，2020，21（3）：725.

TAKADA A，SHIBATA T，SHIGA T，et al. Pharmacokinetic/pharmacodynamic modeling of roxadustat’s effect on LDL cholesterol in patients in Japan with dialysis-dependent chronic kidney disease and anemia[J]. Drug Metab Pharmacokinet，2022，46：100461.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰